France· FR:66862731
ONGLYZA 5 mg, comprimé pelliculé
A saxagliptin product containing chlorhydrate de saxagliptine, registered in France by ASTRAZENECA AB, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Saxagliptin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BH03 (saxagliptin), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Saxagliptin · ATC A10BH03
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of saxagliptin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.31 in France to $3.59 in Italy — a ×12 gap.
- France: $0.31 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Saxagliptin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- IT Italy$3.59
- CH Switzerland$3.41
- FR France$0.31
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE DE SAXAGLIPTINE
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- A10BH03
- ATC class
- Saxagliptin
- Defined daily dose
- 5 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093973588730 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) pré-découpées unidoses.EUR 14.02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
449 interactions on record for saxagliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Saxagliptin · interactions on record
449 records
- 3 severe
- 404 moderate
- 42 minor
Most severe, free to view
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Saxagliptin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaONGLYZAAstraZeneca AB, Södertälje
- SpainONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- BelgiumOnglyza 5 mgAstraZeneca
- United StatesSaxagliptinAurobindo Pharma Limited
- NetherlandsOnglyza 5 mg, filmomhulde tablettenAstraZeneca AB
- IcelandOnglyzaAstraZeneca AB
- NorwayOnglyzaOrifarm AS
- PolandOnglyzaAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Saxagliptin Sandoz, Saxagliptin Zydus Pharmaceuticals Uk
- Hungary · Saxagliptin Pharos
- Iceland · Onglyza
- Liechtenstein · Onglyza
- Malta · Saxagliptin Pharos
- Netherlands · Saxagliptine Sandoz
- Norway · Onglyza
- Portugal · Saxagliptina Generis, Saxagliptina Generis Phar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9f405a55-0824-4acb-8dc9-6c051683dd7e GET /v1/drugs/9f405a55-0824-4acb-8dc9-6c051683dd7e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66862731",
"date_amm": "2009-10-01",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/09/545",
"substance": "CHLORHYDRATE DE SAXAGLIPTINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.